BACKGROUND Loss of negative feedback inhibition of renin release during chronic treatment with an angiotensin-converting enzyme (ACE) inhibitor leads to a compensatory rise in renin secretion and downstream components of the renin-angiotensin-aldosterone (RAAS) cascade. This may overcome ACE inhibition but should be blocked by a direct renin inhibitor. We studied the effects of adding the direc...

BACKGROUND There is insufficient evidence whether the benefit of adding angiotensin II receptor blockers (ARBs) to angiotensin-converting enzyme (ACE) inhibitors outweighs the increased risk of adverse effects in patients with heart failure. METHODOLOGY/PRINCIPAL FINDINGS Two independent reviewers searched and abstracted randomized controlled trials of ARBs and ACE inhibitors compared to ACE ...

Hipertensi merupakan salah satu masalah kesehatan terbesar yang menjadi penyebab utama kematian di seluruh dunia. Angiotensin converting enzyme inhibitor (ACE-I) sebagai obat antihipertensi umum diketahui memiliki efek samping sering dikeluhkan. Penelitian ini bertujuan untuk mengidentifikasi senyawa potensial berasal dari pala (Myristica fragrans) dengan menggunakan studi penambatan molekular....

Chronic kidney disease (CKD) is progressive that closely related to the chronic inflammatory process.Angiotensin-Converting Enzyme Inhibitor (ACE-I)/Angiotensin Receptor Blockers (ARBs) main therapy in management of CKD, based on recent sudies stated this drug have pleiotropic effects as anti-inflammation.The aim study tosee interaction hs-CRP and HDL-Cholesterol prove role ACE-I/ARBs an anti-i...

ACE2, initially cloned from a human heart, is a recently described homologue of angiotensin-converting enzyme (ACE) but contains only a single enzymatic site that catalyzes the cleavage of angiotensin I to angiotensin 1-9 [Ang(1-9)] and is not inhibited by classic ACE inhibitors. It also converts angiotensin II to Ang(1-7). Although the role of ACE2 in the regulation of the renin-angiotensin sy...

METHODS Trials of ACE inhibitor therapy following MI reported between January, 1978 and August, 1997 were identified. Studies were included if they met the following criteria: 1) randomized comparison of ACE inhibitor to placebo within 14 days of MI; 2) study duration/blinded follow-up of $6 weeks; 3) the number of deaths and modes of death were reported or could be obtained from the investigat...

The inhibitory activity of an angiotensin I-converting enzyme (ACE) detected in soy sauce was fractionated into two major fractions ef high molecular weight (Hw) and low molecular weight (Lw) by gel fi1tration chromatography on Bio-gel P-2 after treatifig with ethanol. The Hw fractien reduced the blood pressure in hypertensive rats after orally administering, while the Lw fraction did not. The ...

Angiotensin-converting enzyme (ACE) inhibitors were developed based on proline-rich oligopeptides found in the venom of Bothrops jararaca (Bj) previously known as bradykinin-potentiating peptides (BPPs). However, the exact mechanism of action of BPPs remains unclear. The role of the ACE in the cardiovascular effects of two of naturally proline-rich oligopeptides (Bj-BPP-7a and Bj-BPP-10c) was e...

Angiotensin converting enzyme (ACE) catalyses the conversion of angiotensin I (Ang I) to angiotensin II (Ang II). The ACE activity directly related to hypertension as Ang II is the blood pressure regulating hormone. Therefore, ACE inhibitors are a major class of antihypertensive drugs. Captopril, chemical name, was the first orally active ACE inhibitory antihypertensive drug, discovered in 1977...